FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Singapore Airlines in Discussions with Airbus, Boeing for New Jet Order

By

Singapore Airlines (SGX:C6L) is in negotiations with Airbus and Boeing to purchase at least 50 large wide-body jets, Reuters reported on Thursday, citing two industry sources.

The airline company is seeking offers for either a Boeing 777X model or an Airbus A350-1000, with negotiations still at an early stage, the report said.

This comes after the company had outlined its intention to continue expanding its capacity, despite competitors pulling back, the report added.

The new orders are expected to help the company in the next phase of its growth, the report said.

Singapore Airlines was cited in the report as saying that fleet renewal is being reviewed regularly, but refused to comment on "any confidential discussions that we may or may not be having." Meanwhile, both Boeing and Airbus declined to comment, Reuters said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Sichuan Biokin Pharmaceutical Secures China Clinical Trial Approval for Lymphoma Injection

China's drug regulator approved Sichuan Biokin Pharmaceutical's (SHA:688506) clinical trial for its BL-M08D1 injection as a combination therapy for diffuse large B-cell lymphoma, according to a Friday filing with the Shanghai bourse.Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, according to the Mayo Clinic.BL-M08D1 is also undergoing phase 1B trials for relapsed or refractory hematologic malignancies and locally advanced tumors.

$SHA:688506
Asia

Correction: GuocoLand's Malaysian Unit Moves Closer to Delisting Following High Court Petition

(Corrects the first paragraph to fix a typo and clarify the unit's name)GuocoLand's (SGX:F17) Malaysia-listed unit, GuocoLand (Malaysia) (KLSE:GUOCO), filed a formal petition with the High Court of Malaysia to confirm its proposed share capital reduction and repayment framework, according to a Thursday filing.The court application, submitted on June 4, serves as the primary legal step remaining to execute the company's privatization via a selective capital reduction mechanism.This follows the property developer's shareholders approving the proposed privatization of the company at an extraordinary general meeting held on May 29.

$KLSE:GUOCO$SGX:F17
Asia

Mabwell Receives U.S., China Regulatory Nod to Begin Trials of IBD Drug

Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) has received regulatory approval in China and the U.S. to begin clinical trials of 9MW5211, which targets inflammatory bowel disease (IBD), according to a Thursday filing with the Hong Kong bourse.The company's Hong Kong shares fell over 1% in morning trade Friday.

$HKG:2493$SHA:688062